Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lutetium-177 NY 104 - Norroy Bioscience

Next Previous
X
Search
Drug Profile

Lutetium-177 NY 104 - Norroy Bioscience

Alternative Names: 177Lu-NY104; Lutetium-177 NY-104

Latest Information Update: 27 Aug 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Norroy Bioscience
  • Class Antineoplastics; Radioisotopes; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Renal cancer

Most Recent Events

  • 02 Aug 2024 Norroy Bioscience intends to file a regulatory application for approval of Lutetium-177 NY 104 for Renal cancer in the second half of 2027 (Norroy Bioscience pipeline, July 2024)
  • 31 Jul 2024 Preclinical trials in Renal cancer in China (Parenteral) (Norroy Bioscience pipeline; July 2024)
  • 31 Jul 2024 Norroy Bioscience plans a IND-enabling studies for Renal cancer in first half of 2025 (Norroy Bioscience pipeline; July 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top